Akari Therapeutics Plc: 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K, dated May 20, 2026, reports that Akari Therapeutics Plc (Nasdaq: AKTX) entered into a Securities Purchase Agreement for a private placement offering. The company is incorporated in England and Wales with principal executive offices in Tampa, Florida.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5.5 million (excluding proceeds from Pre-Funded Warrant exercises).
- Transaction Fees: Approximately $125,000 in placement agent fees and expenses.
- Securities Issued: 1,470,588 American Depository Shares (ADSs) or Pre-Funded Warrants, each accompanied by Series H, I, and J warrants.
- Purchase Price: $3.74 per Unit (ADS + Warrants) or $3.739 per Pre-Funded Unit.
- Placement Agent Compensation: 2% cash fee plus 117,647 ADSs (8% of total issuance).
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Transaction Structure
The offering is structured to close in three tranches on or about May 27, 2026, June 15, 2026, and July 15, 2026. The issuance of the Series Warrants and Placement Agent ADSs is contingent upon shareholder approval. Upon approval, the Series Warrants will be exercisable immediately at $3.74 per ADS. The company has agreed to file a registration statement (Form S-3 or S-1) within 30 days of the third closing to register the resale of these securities.
Guidance, Risks, and Contingencies
The filing does not provide updated financial guidance or management commentary regarding operational performance. Key contingencies include the requirement for shareholder approval to finalize the issuance of warrants and placement agent shares. The securities were offered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, relying on the purchasers being accredited investors.
Investor Verification Checklist
- Confirm the status of the required shareholder approval for the Series Warrants and Placement Agent ADSs.
- Verify the actual closing dates and amounts funded across the three tranches (May, June, July 2026).
- Review the filed registration statement (Form S-3 or S-1) for resale registration details.
- Assess the dilution impact of the 1,470,588 ADSs and the associated warrants on existing shareholders.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants.